Division of BioMedical Sciences, Faculty of Medicine, Craig L. Dobbin Genetics Research Centre, Memorial University of Newfoundland, Health Science Centre, 300 Prince Philip Drive, St. John's, NL, A1B 3V6, Canada.
Adv Biol Regul. 2020 Dec;78:100756. doi: 10.1016/j.jbior.2020.100756. Epub 2020 Sep 19.
PKC isozymes have been put in place as oncoproteins since the discovery that they can function as receptors for potent tumor-promoting phorbol esters in the 1980s. Despite nearly two decades of research, a clear in vivo proof of that concept was missing. The availability of so-called knock out mouse lines of individual PKC genes provided a tool to investigate isozyme specific in vivo functions in the context of tumor initiation, development and progression. This review aims to provide a limited overview of how the application of these mouse lines in combination with a cancer mouse model helped to understand PKC's in vivo function during tumorigenesis. The focus of this review will be on skin, colon and lung cancer.
蛋白激酶 C（PKC）同工酶自 20 世纪 80 年代发现其可作为强效肿瘤促进佛波酯的受体以来，一直被视为癌蛋白。尽管近二十年的研究，但该概念在体内的明确证据仍缺乏。所谓的单个 PKC 基因敲除鼠系的出现为研究肿瘤起始、发展和进展过程中同工酶的特定体内功能提供了工具。本综述旨在简要概述这些鼠系与癌症小鼠模型联合应用如何帮助理解 PKC 在肿瘤发生过程中的体内功能。本综述的重点将放在皮肤癌、结肠癌和肺癌上。
